DS
ONC

David Shaw’s BeOne Medicines Ltd ONC Stock Holding History

David Shaw’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,600
Closed -$475K – 5316
2026
Q1 		$475K Sell
1,600
-800
-33% -$259K ﹤0.01% 3875
2025
Q4 		$729K Buy
+2,400
New +$786K ﹤0.01% 3733
2022
Q2 		– Sell
-10,000
Closed -$1.89M – 5854
2022
Q1 		$1.89M Buy
+10,000
New +$2.13M ﹤0.01% 3360
2019
Q1 		– Sell
-25,000
Closed -$3.51M – 3989
2018
Q4 		$3.51M Hold
25,000
– – ﹤0.01% 1747
2018
Q3 		$4.31M Buy
+25,000
New +$4.2M 0.01% 1674
2018
Q2 		– Sell
-10,000
Closed -$1.68M – 3927
2018
Q1 		$1.68M Hold
10,000
– – ﹤0.01% 2164
2017
Q4 		$977K Buy
+10,000
New +$915K ﹤0.01% 2585

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

David Shaw's ONC Position: Q3 2025 in Review

David Shaw sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 158,200 shares — an estimated $48M sold.

David Shaw first reported a position in ONC in Q1 2017 and held it in 10 quarters. The position peaked at $38.3M in Q2 2025. 266 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • David Shaw reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • David Shaw sold 158,200 BeOne Medicines Ltd shares in Q3 2025, an estimated $48M.
  • David Shaw first reported a position in BeOne Medicines Ltd in Q1 2017 and held it in 10 quarters.
  • David Shaw's BeOne Medicines Ltd position peaked at $38.3M in Q2 2025.
  • 266 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.